NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval

NANOBIOTIX, a French biotechnology company, has received approval from the United States Medicines Agency (FDA) for a new Phase 2 study. This study will evaluate NBTXR3, a potential radioenhancer, to treat non-small cell lung cancer in unresectable stage III. The protocol for this study was accepted under the aegis of Johnson & Johnson Enterprise Innovation Inc, linked to Janssen Pharmaceutica NV with whom NANOBIOTIX has a global licensing agreement.

The completion of this trial strengthens the collaboration between NANOBIOTIX and the Johnson & Johnson group, aimed at improving treatment options for patients with cancer. Dr. Louis Kayitalire, Chief Medical Officer at NANOBIOTIX, expressed optimism about the potential impact of this protocol on expanding the applications of NBTXR3 in cancer treatments.